Positive trial results for Alzheimer's drug Xanamem
Actinogen Medical has announced positive results for its lead drug Xanamem, reporting that it has demonstrated improved attention and working memory.
The Xanamem low dose-ranging trial was conducted in a population of 107 healthy, cognitively normal older adults aged 50–80 years, with a mean age of 64 years and a gender ratio of one male to two females. Trial participants were randomised to receive either 10 or 5 mg doses of Xanamem or a matching placebo for a six-week treatment period.
In a release to the ASX, Actinogen’s CEO Dr Steven Gourlay said, “We are excited to see the positive clinical data for these lower Xanamem dose levels. Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other conditions that could be safely used alone or in combination with other therapies. Our future clinical trials will evaluate if Xanamem can make a significant improvement in the lives of patients and their families living with serious neurological conditions.”
It is the second trial conducted by Actinogen that has shown positive results for the potential treatment of Alzheimer’s by Actinogen’s lead drug Xanamem moving the Aussie biotech a big step closer to a groundbreaking treatment of a condition that impacts millions worldwide.
Actinogen will now review detailed results of the Xanamem trial with academic and industry experts as it finalises the design of its next Alzheimer’s disease program trial. Detailed results will be published at a future scientific congress and in a peer-reviewed journal.
Serious risks to back pain patients, investigation finds
Fraud, waste and abuse have been uncovered by an ABC Four Corners investigation into...
The church needs a better understanding of dementia: study
More dementia education is needed to assist clergy in supporting those with dementia and their...
Could the gut microbiome help to diagnose Alzheimer's?
A new project exploring the role of the gut microbiome in the early diagnosis of...
